Post hoc analyses identified potential confounders influencing blood pressure responses in both sham control and RDN groups in the SYMPLICITY HTN-3 trial.
What are the predictors of blood pressure response to RDN versus sham control in patients with resistant hypertension?
Post hoc analyses of the SYMPLICITY HTN-3 trial identified potential confounding factors that may explain the unexpected blood pressure responses to renal denervation, informing future trial designs.
Absolute Event Rate: 0% vs 0%
Post hoc analyses, although derived from limited patient cohorts, reveal several potential confounding factors that may partially explain the unexpected blood pressure responses in both the sham control and RDN groups. These hypothesis-generating data further inform the design of subsequent research to evaluate the potential role of RDN in the treatment of resistant hypertension. CLINICALTRIALS.GOV IDENTIFIER: NCT01418261.
Kandzari et al. (Sun,) reported a other. Post hoc analyses identified potential confounders influencing blood pressure responses in both sham control and RDN groups in the SYMPLICITY HTN-3 trial.